Relationship Between Skin Microbiome, Epigenetic Age, and Facial Features in Aging

Clinical Trial Investigating the Relationship Between Skin Microbiome, Epigenetic Biological Age and Facial Morphological Features in Aging Context

The goal of this observational study is to evaluate the effect of age on skin microbiome.

Study Overview

• Status: Completed
• Conditions: Healthy Female Volunteer

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• France
  • Villeurbanne, France
    • Dermscan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

The population to be studied will be women between 25 to 35 years old and between 55 to 65 years old in order to evaluate the relationship between skin collection and saliva sampling and skin measurements.

Description

Inclusion Criteria:

1. Healthy subject;
2. Sex: female
3. Age: 50% having between 25 to 35 years old or 50% between 55 to 65 years old
4. Type: Caucasian
5. Phototype: I to III on the Fitzpatrick scale
6. Subject, having given freely and expressly her informed consent.
7. Subject, psychologically able to understand the study related information and to give a written informed consent;
8. Subject able to comply with protocol requirements;
9. Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study and during all the study.
10. Women between 55 to 65 years old should be menopausal (last menstrual period at least 12 months before the screening visit

Exclusion Criteria:

1. Pregnant or nursing woman or planning a pregnancy during the study;
2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship;
3. Subject who is under guardianship or who is not able to express her consent;
4. Subject in a social or sanitary establishment;
5. Subject suspected to be non-compliant according to the investigator's judgment;
6. Subject having received 6000 euros indemnities for participation in a clinical research in the 12 previous months, including participation in the present study;
7. Subject enrolled in another clinical trial or which exclusion period is not over.
8. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk or which may interfere with the evaluation;
9. Subject suffering from a severe or progressive disease.
10. Subject with current cutaneous inflammatory or infectious processes (eg, acne, herpes), abscess, an unhealed wound, or a cancerous or precancerous lesion on the face that could interfere with the evaluation.
11. Subject with a tattoo, a scar, moles, acne, too many hairs or anything on the studied zones which might interfere with the evaluation.
12. Subject having received injection on the face with botulinum toxin in the year before the screening.
13. Subject having received injection of filling product on the face in the year before the screening visit.
14. Subject having received injection of mesotherapy in the face in the past 6 months before the screening visit.
15. Subject having done a superficial or medium peeling or a superficial scrub on the face within the 2 previous months.
16. Subject having received tensor threads on the face in the two years before the screening visit.
17. Subject having received treatment with a laser, ultrasound or radiofrequency treatment, a dermabrasion, a surgery, a chemical peeling or any other procedure based on active dermal response on the face within the past 6 months.
18. Subject having used LED mask in the three weeks before screening visit

19. Subject undergoing a topical treatment on the face or a systemic treatment:

    • anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study;
    • corticosteroids during the 2 previous weeks and during the study;
    • retinoids, anti-acne treatment and/or immunosuppressors during the 3 previous months and during the study;
    • any medication stabilized for less than one month.
20. Subject having started or changed her oral contraceptive treatment during the three previous months.
21. Subject under oral hormonal substitutive treatment during the year previous the screening visit
22. Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study;
23. Subject having changed her life habits within the previous month and/or during the study;
24. Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day).
25. Subject having started or changed her face care products and or make-up within the previous month

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
young; between 25 to 35 years old
old; between 55 to 65 years old

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Skin microbiome	single time point

Secondary Outcome Measures

Outcome Measure	Time Frame
skin face measurement	single time point
Epigenetic biological age	single time point

Collaborators and Investigators

• Sponsor: Lesaffre International

Study record dates

Study Major Dates

• Study Start (Actual): October 13, 2025
• Primary Completion (Actual): December 11, 2025
• Study Completion (Actual): December 11, 2025

Study Registration Dates

• First Submitted: February 18, 2026
• First Submitted That Met QC Criteria: February 18, 2026
• First Posted (Actual): February 24, 2026

Study Record Updates

• Last Update Posted (Actual): February 24, 2026
• Last Update Submitted That Met QC Criteria: February 18, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: microbiome, skin, epigenetic, aging
• Other Study ID Numbers: 2025-A01505-44

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No